NextCure stock surge puts cash payout and 1.21% Avere stake under the lens
NextCure, Inc. shares nearly tripled on Tuesday after the cancer-drug developer agreed to merge with privately held Avere Therapeutics and pair the transaction with a $320 million financing. Yet current holders are expected to own just 1.21% of the combined company, making the rally a wager on a possible cash distribution, a contingent-value right and a higher public valuation for Avere—not merely the financing headline.
